New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology

References

• Bauer KA, Rosenberg RD. The pathophysiology of the pre-thrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987;70: 343–50.
   PubMed Web of Science ®Google Scholar
• Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586–92.
   PubMed Web of Science ®Google Scholar
• Ratnoff OD, Nebehay WG. Multiple coagulative defects in a patient with the Waterhouse-Friderichsen syndrome. Ann Intern Med 1962;56:627.
   Google Scholar
• Levi M, ten Cate H, van der Poll T. Disseminated intravas-cular coagulation: state of the art. Thromb Haemost 1999;82: 695–705.
   PubMed Web of Science ®Google Scholar
• Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207–14.
   PubMed Web of Science ®Google Scholar
• Hambleton J, Leung LL, Levi M. Coagulation: consultative hemostasis. Hematology (Am Soc Hematol Educ Program) 2002:335–52.
   Google Scholar
• Shimamura K, Oka K, Nakazawa M, Kojima M. Distribution patterns of microthrombi in disseminated intravascular coagulation. Arch Pathol Lab Med 1983;107:543–7.
   Google Scholar
• Levi M, van Gorp E, ten Cate H. Disseminated Intravascular Coagulation. In: Handin RI, Lux SE, Stossel TP, eds. Blood. Principle and practice of hematology 2nd edn. Philadelphia: Lippincott; 2003:1275–301.
   Google Scholar
• Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FBJ, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993;91:2850–6.
   PubMed Web of Science ®Google Scholar
• Kessler CM, Tang Z, Jacobs HM, Szymanski LM. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997;89:4393–401.
   PubMed Web of Science ®Google Scholar
• Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816–23.
   Google Scholar
• Levi M. Cancer and DIC. Haemostasis 2001;31:47–8.
   Google Scholar
• Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infec-tion: related to an unfavourable prognosis. Thromb Haemost 1983;49:5–7.
   PubMed Web of Science ®Google Scholar
• Franco RF, de Jonge E, Dekkers PE, Timmerman JJ, Spek CA, van Deventer SJ, et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood 2000; 96: 554–9.
   PubMed Web of Science ®Google Scholar
• van der Poll T, Levi M, Hack CE, ten Cate H, van Deventer SJ, Eerenberg A J, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chim-panzees. J Exp Med 1994;179:1253–9.
   PubMed Web of Science ®Google Scholar
• Levi M, van der Poll T, ten Cate H, van Deventer S J. The cytokine-mediated imbalance between coagulant and antic-oagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997;27:3–9.
   PubMed Web of Science ®Google Scholar
• Marshall JC. Inflammation, coagulopathy, and the pathogen-esis of multiple organ dysfunction syndrome. Crit Care Med 2001;29:S99–106.
   Google Scholar
• ten Cate H, Bauer KA, Levi M, Edgington TS, Sublett RD, Barzegar S, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993;92:1207–12.
   PubMed Web of Science ®Google Scholar
• Seitz R, Wolf M, Egbring R, Havemann K. The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Eur J Haematol 1989;43:22–8.
   PubMed Web of Science ®Google Scholar
• Bourin MC, Lindahl U. Glycosaminoglycans and the regula-tion of blood coagulation. Biochem J 1993;289:313–30.
   PubMed Web of Science ®Google Scholar
• Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001;29:S90–S94.
   Google Scholar
• Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989264:4743–6.
   Google Scholar
• Fukudome K, Esmon CT. Identification, cloning, and regula-tion of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994;269:26486–91.
   PubMed Web of Science ®Google Scholar
• Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986; 83:3460–4.
   PubMed Web of Science ®Google Scholar
• Moore KL, Esmon CT, Esmon NL. Tumor necrosis factor leads to the internalization and degradation of thrombomo-dulin from the surface of bovine aortic endothelial cells in culture. Blood 1989;73:159–65.
   Google Scholar
• Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345:408–16.
   PubMed Web of Science ®Google Scholar
• Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagula-tion inhibitor in patient samples. Blood 1991;78:387–93.
   Google Scholar
• Sandset PM, Warn-Cramer BJ, Rao LV, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 1991; 88:708–12.
   PubMed Web of Science ®Google Scholar
• de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, et al. Tissue factor pathway inhibitor (TFPI) dose-dependently inhibits coagulation activtion without influencing the fibrinolytic and cytokine response during human endotox-emia. Blood 2000;95:1124–9.
   PubMed Web of Science ®Google Scholar
• Levi M. The imbalance between tissue factor and tissue factor pathway inhibitor in sepsis. Crit Care Med 2002;30:1914–5.
   Google Scholar
• Gando S, Kameue T, Morimoto Y, Matsuda M, Hayakawa M, Kemmotsu 0. Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 2002;30:1729–34.
   Google Scholar
• Biemond BJ, Levi M, ten Cate H, van der Poll T, Buller HR, Hack CE, et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxae-mia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond) 1995;88:587–94.
   Google Scholar
• Mesters RM, Florke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996; 75:902–7.
   PubMed Web of Science ®Google Scholar
• Westendorp RG, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningo-coccal septic shock. Lancet 1999;354: 561–3.
   Google Scholar
• Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991;88:1346–53.
   Google Scholar
• Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996;97:2440–51.
   PubMed Web of Science ®Google Scholar
• Altieri DC. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem 1994;269:3139–42.
   PubMed Web of Science ®Google Scholar
• Camerer E, Huang W, Coughlin SR. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000;97: 5255–60.
   Google Scholar
• Degen JL. Hemostatic factors and inflammatory disease. Thromb Haemost 1999;82:858–64.
   Google Scholar
• Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103:879–87.
   PubMed Web of Science ®Google Scholar
• Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258–64.
   PubMed Web of Science ®Google Scholar
• Cunningham MA, Romas P, Hutchinson P, Holdsworth SR, Tipping PG. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood 1999;94:3413–20.
   Google Scholar
• de Jonge E, Friederich PW, Levi M, van der Poll T. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin-6 and interleukin-8 release in healthy human subjects. Clin Diagn Lab Immunol 2003;10: 495–7.
   Google Scholar
• Esmon CT. Does inflammation contribute to thrombotic events? Haemostasis 2000;30:34–40.
   PubMedGoogle Scholar
• Hancock WW, Tsuchida A, Hau H, Thomson NM, Salem HH. The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy. Transplant Proc 1992;24:2302–3.
   Google Scholar
• Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.
   Google Scholar
• Minnema MC, Chang AC, Jansen PM, Lubbers YT, Pratt BM, Whittaker BG, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000;95:1117–23.
   PubMed Web of Science ®Google Scholar
• Alving BM, Spivak JL, DeLoughery TG. Consultative hema-tology: Hemostasis and transfusion issues in surgery and critical care medicine. Hematology 1998:320–41.
   Google Scholar
• Feinstein DI. Diagnosis and management of disseminated intravascular coagulation:the role of heparin therapy. Blood 1982;60:284–7.
   PubMed Web of Science ®Google Scholar
• Dorffler-Melly J, de Jonge E, de Pont AC, Buller HR, Vroom MB, Levi M. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002;359: 849–50.
   Google Scholar
• Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001;29:2081–9.
   Google Scholar
• Warren BL, Lid A, Singer P, Pillay SS, Carl P, Novak I, et al. Caring for the critically ill patient. High-dose antithrombin III
   Google Scholar
• Taylor FBJ, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick et al. Protein C prevents the coagulopathic
   Google Scholar
• Esmon CT. Introduction: are natural anticoagulants candidates for modulating the inflammatory response to endotoxin? Blood 2000;95:1113–6.
   Google Scholar
• Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003;31:\83110.
   Google Scholar
• Levi M. Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death. Crit Care Med 2003;31:984–5.
   Google Scholar